Comparison of efficacy of topical tazarotene 0.1% versus topical adapalene 0.1% in treatment of mild to moderate acne vulgaris
Keywords:
Acne, Acne vulgaris, Tazarotene, Adapalene, Topical retinoidsAbstract
ABSTRACT Background: Acne vulgaris, a prevalent skin condition characterized by comedones, papules, and pustules, not only affects physical appearance but also causes emotional distress and scarring. Treatment options primarily encompass topical agents such as tazarotene 0.1% and adapalene 0.1%. However, a notable gap persists in comparative efficacy studies between these formulations, underscoring the need for robust clinical research to guide therapeutic choices effectively. Methods: One hundred and eight six patients meeting inclusion criteria were enrolled in the study. Informed written consent was taken and two groups were made using lottery method. In patients of group A, tazarotene was applied while in group B topical adapalene was administered Patients were reviewed on 4th week, 8th week and 12th week and report severe side effects immediately, if any. Patients were instructed to refrain from using cosmetics and other topical applications on their face. Data was noted and analyzed using SPSS version 20.0. Results: In this study, 186 participants aged between 17 to 32 years (mean age: 23.10 ± 3.2 years) were included, comprising 82 males (44.09%) and 104 females (55.91%). The mean BMI of the participants was 21.52 ± 2.06 kg/m². Both the groups had insignificant difference between the groups with regard to baseline characteristics (p-value>0.05). At Week 0, both groups exhibited comparable mean scores of 12.28 ± 5.27, with no statistically significant variance observed (p = 1.000). By Week 4, slight reductions were noted in both groups, with Group A reporting a mean score of 10.24 ± 4.70 and Group B reporting 10.58 ± 4.61 (p = 0.615). However, at Week 8 (5.81±3.45 vs. 8.01±3.87; p-value <0.001) and 12 (0.72±1.77 vs. 3.93±3.70; p-value<0.001), mean score was significantly less in group A than group B. In terms of efficacy, Group A demonstrated a higher frequency of positive outcomes, with all 93 participants (100.0%) experiencing the desired effect. In contrast, Group B showed a slightly lower efficacy rate, with 70 out of 93 participants (75.3%) achieving the desired outcome. Stratification of treatment response and efficacy produced similar results for all sub groups. Conclusion: Both therapies showed statistically significant results however patients treated with 0.1% tazarotene showed more efficacious results as compared to 0.1% adapalene. KEY WORDS: Acne, Acne vulgaris, Adapalene, Tazarotene, Topical RetinoidsReferences
Markovic M, Soldatovic I, Bjekic M, Sipetic-Grujicic S. Adolescents’ self-perceived acne-related beliefs: from myth to science. An Bras Dermatol. 2020;94(4):684-90.
Rigopoulos D, Gregoriou S, Ifandi A, Efstathiou G, Georgala S, Chalkias J, et al. Coping with acne: beliefs and perceptions in a sample of secondary school Greek pupils. J Eur Acad Dermatol Venereol. 2007;21(6):806-10.
Tan J, Draelos ZD, Gooderham MJ, Alexis AF, Graber E, Keri J, et al. Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne. J Clin Aesthet Dermatol. 2023;16(9):42-5.
Han G, Wu JJ, Del Rosso JQ. Use of topical tazarotene for the treatment of acne vulgaris in pregnancy: a literature review. J Clin Aesthet Dermatol. 2020;13(9):E59-65.
Pathmarajah P, Peterknecht E, Cheung K, Elyoussfi S, Muralidharan V, Bewley A. Acne vulgaris in skin of color: a systematic review of the effectiveness and tolerability of current treatments. J Clin Aesthet Dermatol. 2022;15(11):43-68.
Gallitano SM, Berson DS. How acne bumps cause the blues: the influence of acne vulgaris on self-esteem. Int J Women Dermatol. 2018;4(1):12-7.
Tsai J, Chien AL. Photoprotection for skin of color. Am J Clin Dermatol. 2022;23(2):195-205.
Cooper BR, Anderson JB, Laughter MR, Presley CL, Albrecht JM, Dellavalle RP. Top skin-of-color publications in dermatology. JMIR Dermatol. 2022;5(2):e37256.
H Alfalogy E, H Hariri N, T Yamani I, H Al-Mosa W, D Majrashi R. Epidemiology of acne vulgaris: prevalence, severity and its impact among school teenagers in Makkah, Saudi Arabia. Egypt Fam Med J. 2018;2(1):1-2.
Skroza N, Tolino E, Mambrin A, Zuber S, Balduzzi V, Marchesiello A, et al. Adult acne versus adolescent acne: a retrospective study of 1,167 patients. J Clin Aesthet Dermatol. 2018;11(1):21-5.
Kashyap S, Besra L, Kar HK, KAR HK. evaluation of risk factors associated with adult-onset acne in patients attending a tertiary care center in east india: a case-control study. Cureus. 2024;16(1):e53296.
Saha B, Mendiratta V. Evaluating the body mass index, blood glucose, and serum insulin in adolescent acne. Ind J Paediatr Dermatol. 2023;24(1):19-23.
Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drug Dermatol. 2008; 7(6 Suppl):s3-10.
Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.
Waugh J, Noble S, Scott LJ. Spotlight on adapalene in acne vulgaris. Am J Clin Dermatol. 2004;5(5):369-71.
Safety and efficacy of tazarotene cream 0.1% compared with adapalene gel 0.3% in the treatment of moderate to severe facial acne vulgaris. 2012; Clinical Trials.gov Identifier: NCT00829049.
Yentzer BA, Irby CE, Fleischer Jr AB, Feldman SR. Differences in acne treatment prescribing patterns of pediatricians and dermatologists: an analysis of nationally representative data. Pediatr Dermatol. 2008;25(6):635-9.
Wolf Jr JE, Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J AM Acad Dertmatol. 2003;49(3):S211-7.
Anjum R, Majeed R, Dawood N, Shahzadi S, Sheikh F, Sheikh M. Efficacy and side effects estimation of 5% dapsone gel in the treatment of mild to moderate acne vulgaris. J Pak Assoc Dermatol. 2023;33(4):1524-8.
Bava A, Joy B, Anoop T, Sridharan R, Sreenivasan A. Effect of 30 percent salicylic acid peels in mild to moderate acne vulgaris: a hospital-based nonrandomised clinical study. J Pak Med Assoc Dermatol. 2018;28(2):146-51.
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(1):S1-37.
Pariser D, Colón LE, Johnson LA, Gottschalk RW. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drug Dermatol. 2008;7(6 Suppl):s18-23.
Singh R, Rao N. Acne & Scars. JP Medical Ltd; 2016 Apr 10.
Micali G, Lacarrubba F, Nasca MR, Ferraro S, Schwartz RA. Topical pharmacotherapy for skin cancer: part II. Clinical applications. J Am Acad Dermatol. 2014;70(6):979-85.
Gold LS, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate and severe inflammatory acne vulgaris effectively treated with single-agent therapy by a new fixed-dose combination adapalene 0.3%/benzoyl peroxide 2.5% gel: a randomized, double-blind, parallel-group, controlled study. Am J Clin Dermatol. 2016;17(3):293-303.
Seaton E, Mouser P, Charakida A, Alam S, Seldon P, Chu A. Investigation of the mechanism of action of nonablative pulsed dye laser therapy in photorejuvenation and inflammatory acne vulgaris. Br J Dermatol. 2006;155(4):748-55.